����������

The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B Program is a vital lifeline for hospitals, particularly those serving rural and low-income communities,” AHA said. “If HHS authorizes these proposed ‘rebate models,’ it would come at the expense of America’s most vulnerable patients and communities.” HHS recently announced that it will be “in a position to provide guidance” about the drug industry’s proposed use of “rebate models” by the end of May.